Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity.

MLA

Yamamoto, Brent J., et al. “Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity.” Antimicrobial Agents and Chemotherapy, vol. 60, no. 10, Sept. 2016, pp. 5787–95. EBSCOhost, https://doi.org/10.1128/AAC.00972-16.

APA

Yamamoto, B. J., Shadiack, A. M., Carpenter, S., Sanford, D., Henning, L. N., O’Connor, E., Gonzales, N., Mondick, J., French, J., Stark, G. V., Fisher, A. C., Casey, L. S., & Serbina, N. V. (2016). Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity. Antimicrobial Agents and Chemotherapy, 60(10), 5787–5795. https://doi.org/10.1128/AAC.00972-16

Chicago

Yamamoto, Brent J, Annette M Shadiack, Sarah Carpenter, Daniel Sanford, Lisa N Henning, Edward O’Connor, Nestor Gonzales, et al. 2016. “Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity.” Antimicrobial Agents and Chemotherapy 60 (10): 5787–95. doi:10.1128/AAC.00972-16.